Neuroimmune communication regulating pruritus in atopic dermatitis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a common, chronic-relapsing inflammatory skin disease with significant disease burden. Genetic and environmental trigger factors contribute to AD, activating 2 of our largest organs, the nervous system and the immune system. Dysregulation of neuroimmune circuits plays a key role in the pathophysiology of AD, causing inflammation, pruritus, pain, and barrier dysfunction. Sensory nerves can be activated by environmental or endogenous trigger factors, transmitting itch stimuli to the brain. On stimulation, sensory nerve endings also release neuromediators into the skin, contributing again to inflammation, barrier dysfunction, and itch. In addition, dysfunctional peripheral and central neuronal structures contribute to neuroinflammation, sensitization, nerve elongation, and neuropathic itch, thus chronification and therapy resistance. Consequently, neuroimmune circuits in skin and central nervous system may be targets to treat pruritus in AD. Cytokines, chemokines, proteases, lipids, opioids, and ions excite/sensitize sensory nerve endings, which not only induces itch but further aggravates/perpetuates inflammation, skin barrier disruption, and pruritus as well. Thus, targeted therapies for neuroimmune circuits as well as pathway inhibitors (eg, kinase inhibitors) may be beneficial to control pruritus in AD either in systemic and/or in topical form. Understanding neuroimmune circuits and neuronal signaling will optimize our approach to control all pathological mechanisms in AD, inflammation, barrier dysfunction, and pruritus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180
Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing
Usoskin, D., Furlan, A., Islam, S., Abdo, H., Lönnerberg, P., Lou, D., Hjerling-Leffler, J., Haeggström, J., Kharchenko, O., Kharchenko, P. V., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3881 · Cited by 2,136
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
The metabolic signature of macrophage responses
Viola, A., Munari, F., Sánchez-Rodríguez, R., Scolaro, T., & Castegna, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01462 · Cited by 2,021
Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Ito, T., Wang, Y.-H., Duramad, O., Hori, T., Delespesse, G. J., Watanabe, N., Qin, F. X.-F., Yao, Z., Cao, W., & Liu, Y.-J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051135 · Cited by 1,129
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Commensal bacteria regulate Toll-like receptor 3–dependent inflammation after skin injury
Lai, Y., Di Nardo, A., Nakatsuji, T., Leichtle, A., Yang, Y., Cogen, A. L., Wu, Z.-R., Hooper, L. V., Schmidt, R. R., von Aulock, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.2062 · Cited by 781
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
The Cells and Circuitry for Itch Responses in Mice
Mishra, S. K., & Hoon, M. A. (2013) · Science · doi:10.1126/science.1233765 · Cited by 507
Lai, Y., Cogen, A. L., Radek, K. A., Park, H. J., MacLeod, D. T., Leichtle, A., Ryan, A. F., Di Nardo, A., & Gallo, R. L. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.123 · Cited by 446
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Yosipovitch, G., Greaves, M. W., & Schmelz, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12570-6 · Cited by 388
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Simpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.059 · Cited by 328
Han, H., Roan, F., & Ziegler, S. F. (2017) · Immunological Reviews · doi:10.1111/imr.12546 · Cited by 285
Lipid abnormalities in atopic skin are driven by type 2 cytokines
Berdyshev, E., Goleva, E., Bronova, I., Dyjack, N., Rios, C., Jung, J., Taylor, P., Jeong, M., Hall, C. F., Richers, B. N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98006 · Cited by 283
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908316 · Cited by 281
Self-citationSilverberg, J. I., Pinter, A., Pulka, G., Poulin, Y., Bouaziz, J.-D., Wollenberg, A., Murrell, D. F., Alexis, A., Lindsey, L., Ahmad, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.013 · Cited by 271
Self-citationCircuit dissection of the role of somatostatin in itch and pain
Huang, J., Polgár, E., Solinski, H. J., Mishra, S. K., Tseng, P.-Y., Iwagaki, N., Boyle, K. A., Dickie, A. C., Kriegbaum, M. C., Wildner, H., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0119-z · Cited by 257
The Itch–Scratch Cycle: A Neuroimmune Perspective
Mack, M. R., & Kim, B. S. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.001 · Cited by 255
Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2945 · Cited by 250
Kabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Nakano, M., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.018 · Cited by 248
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226
Guttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220
Fang, Z., Li, L., Zhang, H., Zhao, J., Lu, W., & Chen, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720393 · Cited by 200
Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., Spooner, J., Keen, J., Minter, R., Uddin, F., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.005 · Cited by 198
Therapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab
Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R. F., Wu, L. C., & Eigenbrot, C. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.024 · Cited by 174
Renert-Yuval, Y., Del Duca, E., Pavel, A. B., Fang, M., Lefferdink, R., Wu, J., Diaz, A., Estrada, Y. D., Canter, T., Zhang, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.001 · Cited by 168
The skin microbiome is different in pediatric versus adult atopic dermatitis
Shi, B., Bangayan, N. J., Curd, E., Taylor, P. A., Gallo, R. L., Leung, D. Y. M., & Li, H. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.053 · Cited by 161
Ständer, S., Kwon, P., Hirman, J., Perlman, A. J., Weisshaar, E., Metz, M., & Luger, T. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.052 · Cited by 118
Luminal Cathepsin G and Protease-Activated Receptor 4
Dabek, M., Ferrier, L., Roka, R., Gecse, K., Annahazi, A., Moreau, J., Escourrou, J., Cartier, C., Chaumaz, G., Leveque, M., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080986 · Cited by 73
Spinal somatostatin-positive interneurons transmit chemical itch
Fatima, M., Ren, X., Pan, H., Slade, H. F. E., Asmar, A. J., Xiong, C. M., Shi, A., Xiong, A. E., Wang, L., & Duan, B. (2019) · Pain · doi:10.1097/j.pain.0000000000001499 · Cited by 41
Klaeschen, A. S., Nümm, T. J., Herrmann, N., Leib, N., Maintz, L., Sakai, T., Wenzel, J., & Bieber, T. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.041 · Cited by 36
Henehan, M., & De Benedetto, A. (2019) · Experimental Dermatology · doi:10.1111/exd.13936 · Cited by 28
Yamamoto, Y., Otsuka, A., Nakashima, C., Ishida, Y., Honda, T., Egawa, G., Amano, W., Usui, K., Hamada, Y., Wada, M., et al. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.12.008 · Cited by 26
Chemokine neutralization as an innovative therapeutic strategy for atopic dermatitis
Abboud, D., & Hanson, J. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.023 · Cited by 24
Cited by
Domaszewska-Szostek, A., Krzyżanowska, M., Polak, A., & Puzianowska-Kuźnicka, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052354 · Cited by 32
“Furthermore, an overactivated neuroimmunoendocrine system may exacerbate pre-existing inflammatory skin disorders, such as psoriasis or atopic dermatitis, contributing to a more severe and treatment-resistant disease course [14].”
CLA+ memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis
Nicolàs, L. S. S., Czarnowicki, T., Akdis, M., Pujol, R. M., Lozano‐Ojalvo, D., Leung, D. Y. M., Guttman‐Yassky, E., & Santamaria‐Babí, L. F. (2024) · Allergy · doi:10.1111/all.15816 · Cited by 25
“109,110 IL-31 is a neuroimmune cytokine that was originally described as mainly produced by CLA + memory Th2 cells in AD, 64,111,112 with implications in pruritus, inflammation, fibrosis and epidermal barrier dysfunction.”
BackgroundAndrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
“The IL-31/IL-31RA immune axis may also contribute to inflammatory processes and skin barrier dysfunction, although the precise mechanisms underlying its action remain unclear [101].”
Metadata
- Authors
- Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 149
- Issue
- 6
- Pages
- 1875-1898
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W4220885146
- Cited by
- 190
- References
- 46
- FWCI
- 27.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.